PineTree Therapeutics

PineTree Therapeutics Inc. is a preclinical-stage biotechnology company and a pioneer in disruptive therapies for oncology and infectious diseases. The company is primarily engaged in the development of disruptive therapies in oncology and immuno-oncology. PineTree Therapeutics, Inc. possesses the MATESM platform technology, which can discover and develop bispecific or multispecific antibodies that may treat so-called "difficult-to-treat" solid tumors caused by a high mutation burden, including undruggable genetic mutants. The lead candidate of PineTree Therapeutics is in the late preclinical trial stage nearing the lead selection phase. Their unique dual-inhibition mechanism generates robust anti-tumor immunity by increasing the quantity and enhances the functionality of cytotoxic CD8 T cells by selectively inhibiting regulatory T cells present only in tumors and not in the peripheral blood system. Moreover, it exerts a potent direct anti-tumor effect on lung adenocarcinoma cells harboring various (undruggable) oncogenic mutations, including KRAS/NRAS, TP53, BRCA2, and others. Therefore, this dual inhibition may result in strong combination efficacy across several cancer types, including lung and pancreatic cancers, within the tumor microenvironment.